[go: up one dir, main page]

ATE118818T1 - Verfahren zur herstellung synthetischer oligonukleotide, die spezifisch an bestimmungsstellen auf duplex-dna-molekülen binden durch formen eines kolinearen triplex, die synthetischen oligonukleotide und verfahren zu ihrer herstellung. - Google Patents

Verfahren zur herstellung synthetischer oligonukleotide, die spezifisch an bestimmungsstellen auf duplex-dna-molekülen binden durch formen eines kolinearen triplex, die synthetischen oligonukleotide und verfahren zu ihrer herstellung.

Info

Publication number
ATE118818T1
ATE118818T1 AT89313391T AT89313391T ATE118818T1 AT E118818 T1 ATE118818 T1 AT E118818T1 AT 89313391 T AT89313391 T AT 89313391T AT 89313391 T AT89313391 T AT 89313391T AT E118818 T1 ATE118818 T1 AT E118818T1
Authority
AT
Austria
Prior art keywords
synthetic oligonucleotides
dna
bind
duplex
duplex dna
Prior art date
Application number
AT89313391T
Other languages
English (en)
Inventor
Michael Edward Hogan
Donald Joseph Kessler
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Application granted granted Critical
Publication of ATE118818T1 publication Critical patent/ATE118818T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6839Triple helix formation or other higher order conformations in hybridisation assays
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • C12Q1/702Specific hybridization probes for retroviruses
    • C12Q1/703Viruses associated with AIDS
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • C12Q1/705Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • C12Q1/708Specific hybridization probes for papilloma
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y101/00Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01034Hydroxymethylglutaryl-CoA reductase (NADPH) (1.1.1.34)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y205/00Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01018Glutathione transferase (2.5.1.18)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07Nucleotidyltransferases (2.7.7)
    • C12Y207/07007DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/15Nucleic acids forming more than 2 strands, e.g. TFOs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
AT89313391T 1988-12-20 1989-12-20 Verfahren zur herstellung synthetischer oligonukleotide, die spezifisch an bestimmungsstellen auf duplex-dna-molekülen binden durch formen eines kolinearen triplex, die synthetischen oligonukleotide und verfahren zu ihrer herstellung. ATE118818T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28735988A 1988-12-20 1988-12-20

Publications (1)

Publication Number Publication Date
ATE118818T1 true ATE118818T1 (de) 1995-03-15

Family

ID=23102554

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89313391T ATE118818T1 (de) 1988-12-20 1989-12-20 Verfahren zur herstellung synthetischer oligonukleotide, die spezifisch an bestimmungsstellen auf duplex-dna-molekülen binden durch formen eines kolinearen triplex, die synthetischen oligonukleotide und verfahren zu ihrer herstellung.

Country Status (10)

Country Link
EP (2) EP0449972A4 (de)
JP (1) JPH04502407A (de)
AT (1) ATE118818T1 (de)
AU (1) AU640910B2 (de)
CA (1) CA2006008C (de)
DE (1) DE68921315T2 (de)
DK (1) DK120091A (de)
ES (1) ES2069598T3 (de)
PT (1) PT92640B (de)
WO (1) WO1990006934A1 (de)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422251A (en) * 1986-11-26 1995-06-06 Princeton University Triple-stranded nucleic acids
US5928863A (en) * 1986-11-26 1999-07-27 Princeton University Triple-stranded nucleic acids
US5849482A (en) * 1988-09-28 1998-12-15 Epoch Pharmaceuticals, Inc. Crosslinking oligonucleotides
US5721218A (en) * 1989-10-23 1998-02-24 Gilead Sciences, Inc. Oligonucleotides with inverted polarity
US5399676A (en) * 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
IE20010427A1 (en) * 1990-04-10 2003-03-05 Canji Inc Gene therapy for cell proliferative diseases
CA2083719A1 (en) * 1990-05-25 1991-11-26 Mark D. Matteucci "sequence-specific non-photoactivated crosslinking agents which bind to the major groove of duplex dna
EP0463712A3 (en) * 1990-06-27 1992-04-08 University Patents, Inc. Polynucleotide phosphorodithioates as therapeutic agents for retroviral infections
US5734022A (en) * 1990-08-01 1998-03-31 The Johns Hopkins University Antibodies to a novel mammalian protein associated with uncontrolled cell division
WO1992009705A1 (en) * 1990-11-23 1992-06-11 Gilead Sciences, Inc. Triplex-forming oligomers containing modified bases
WO1992011390A1 (en) * 1990-12-17 1992-07-09 Idexx Laboratories, Inc. Nucleic acid sequence detection by triple helix formation
US5683874A (en) * 1991-03-27 1997-11-04 Research Corporation Technologies, Inc. Single-stranded circular oligonucleotides capable of forming a triplex with a target sequence
US6136601A (en) * 1991-08-21 2000-10-24 Epoch Pharmaceuticals, Inc. Targeted mutagenesis in living cells using modified oligonucleotides
CA2116343A1 (en) * 1991-08-30 1993-03-18 Paul S. Miller Formation of triple helix complexes of double stranded dna using nucleoside oligomers which comprise purine base analogs
IL103311A0 (en) * 1991-10-07 1993-03-15 Univ Johns Hopkins Formation of triple helix complexes of single stranded nucleic acids using nucleoside oligomers
US5594121A (en) * 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
WO1993009127A1 (en) * 1991-11-07 1993-05-13 Gilead Sciences, Inc. Enhanced triple-helix formation directed by oligonucleotides composed of 2'-deoxy-7-deazaxanthosine and 2'-deoxy-7-deazaguanosine and related analogs
AU3222793A (en) * 1991-11-26 1993-06-28 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
TW393513B (en) * 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
US5484908A (en) * 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US5616461A (en) * 1992-05-14 1997-04-01 Dana-Farber Cancer Institute Assay for antiviral activity using complex of herpesvirus origin of replication and cellular protein
US6403302B1 (en) 1992-09-17 2002-06-11 California Institute Of Technology Methods and compositions for triple helix formation
WO1994007367A1 (en) * 1992-09-29 1994-04-14 Apollon, Inc. Anti-viral oligomers that bind polypurine tracts of single-stranded rna or rna-dna hybrids
JPH08503366A (ja) * 1992-11-09 1996-04-16 トーマス・ジェファーソン・ユニバーシティ コラーゲンの突然変異および野生型遺伝子の発現を阻害するアンチセンスオリゴヌクレオチド
EP0674707A4 (de) * 1992-12-04 1998-01-14 Apollon Inc Verbindungen und methoden zur behandlung von leukämien.
EP0673260A4 (de) * 1992-12-08 1999-04-14 Genta Inc Bildung von tripelhelix-komplexen mittels einem neuen motif.
AU6296294A (en) * 1993-01-26 1994-08-15 Microprobe Corporation Bifunctional crosslinking oligonucleotides adapted for linking to a desired gene sequence of invading organism or cell
US6323185B1 (en) 1993-04-23 2001-11-27 The United States Of America As Represented By The Department Of Health And Human Services Anti-viral guanosine-rich oligonucleotides and method of treating HIV
US6288042B1 (en) 1993-04-23 2001-09-11 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich tetrad forming oligonucleotides
US5567604A (en) 1993-04-23 1996-10-22 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
KR960703170A (ko) * 1993-06-23 1996-06-19 알버트 디. 프리센. 안티센스 올리고뉴클레오티드 및 인간면역결핍바이러스감염에서 그것의 치료적이용(antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection)
US5962426A (en) 1993-06-25 1999-10-05 Yale University Triple-helix forming oligonucleotides for targeted mutagenesis
WO1995001364A1 (en) * 1993-06-25 1995-01-12 Yale University Chemically modified oligonucleotide for site-directed mutagenesis
CA2174425A1 (en) * 1993-10-18 1995-04-27 Graham Leslie Barrett A method for enhancing neurone survival and agents useful for same
US6136858A (en) 1994-01-10 2000-10-24 Abbott Laboratories Infant formula and methods of improving infant stool patterns
US5700590A (en) * 1994-01-10 1997-12-23 Abbott Laboratories Nutritional formula with ribo-nucleotides
US5492899A (en) * 1994-01-10 1996-02-20 Abbott Laboratories Infant nutritional formula with ribo-nucleotides
US5488039A (en) * 1994-01-10 1996-01-30 Abbott Laboratories Method for the production of an enteral formula containing ribo-nucleotides
US5602109A (en) * 1994-01-10 1997-02-11 Abbott Laboratories Method to enhance the immune system of a human
US5780611A (en) * 1995-09-15 1998-07-14 Ramareddy Venkata Guntaka Oligomers which inhibit expression of collagen genes
US5808037A (en) * 1995-09-15 1998-09-15 Ramareddy Venkata Guntaka Oligomers which inhibit expression of collagen genes
US6156513A (en) * 1995-09-15 2000-12-05 Ramareddy V. Guntaka Oligmers which inhibit expression of collagen genes
FR2746412B1 (fr) * 1996-03-21 1998-06-12 Rhone Poulenc Rorer Sa Purification d'adn plasmidique de qualite pharmaceutique
US6312925B1 (en) * 1997-05-08 2001-11-06 Epoch Pharmaceuticals, Inc. Methods and compositions to facilitate D-loop formation by oligonucleotides
US6930175B1 (en) 1997-12-12 2005-08-16 The Johns Hopkins University School Of Medicine Gene family with transformation modulating activity
CA2370000A1 (en) * 1999-04-08 2000-10-19 Uab Research Foundation Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin
US8114850B2 (en) 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
FR2822156A1 (fr) * 2001-03-16 2002-09-20 Centre Nat Rech Scient Oligonucleotides pour la regulation du gene codant pour le tnf alpha et/ou de genes sous son controle et leurs applications
US8129514B2 (en) 2003-06-19 2012-03-06 Evogene Ltd. Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
WO2004111183A2 (en) 2003-06-19 2004-12-23 Evogene Ltd. Plant trichome-specific promoter and leucoplast signal sequence
CA2614531C (en) 2005-07-07 2015-06-16 Avraham Hochberg Nucleic acid agents for downregulating h19, and methods of using same
US8658608B2 (en) 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
EP2111450A2 (de) 2007-01-16 2009-10-28 Yissum Research Development Company of the Hebrew University of Jerusalem Nukleinsäurekonstrukte und verfahren zur spezifischen stilllegung von h19
EP2200628A2 (de) 2007-07-15 2010-06-30 Yitzchak Hillman Behandlung von krankheiten über antimikrobielle peptide oder ihre inhibitoren
IL184627A0 (en) 2007-07-15 2008-12-29 Technion Res & Dev Foundation Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
US8461303B2 (en) 2007-08-02 2013-06-11 Gilead Biologics, Inc. LOX and LOXL2 inhibitors and uses thereof
US8097712B2 (en) 2007-11-07 2012-01-17 Beelogics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
ES2633786T3 (es) 2008-04-01 2017-09-25 Biosearch Technologies, Inc. Sondas de fluoróforo atenuadoras oscuras de ácido nucleico estabilizado
AU2009298802A1 (en) 2008-09-23 2010-04-08 Alnylam Pharmaceuticals, Inc. Chemical modifications of monomers and oligonucleotides with cycloaddition
WO2010080769A2 (en) 2009-01-06 2010-07-15 Arresto Biosciences, Inc. Chemotherapeutic methods and compositions
US20120020954A1 (en) 2009-03-30 2012-01-26 Anat Achiron Methods of predicting clinical course and treating multiple sclerosis
BR112012008054A2 (pt) 2009-08-21 2017-05-23 Gilead Biologics Inc domínios catalíticos de lisil oxidase e loxl2
CA2770276A1 (en) 2009-08-21 2012-02-24 Beeologics, Inc. Preventing and curing beneficial insect diseases via plant transcribed molecules
US9610331B2 (en) 2009-09-08 2017-04-04 Yeda Research And Development Co. Ltd. Methods for hematopoietic precursor mobilization
US20120171213A1 (en) 2009-09-10 2012-07-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating tumors
CA2777448C (en) 2009-10-14 2023-02-28 Ilan Sela Compositions for controlling varroa mites in bees
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
EP2531217A4 (de) 2010-02-04 2013-11-27 Gilead Biologics Inc Antikörper zur bindung an lysyl-oxidase-like 2 (loxl2) und verwendungsverfahren dafür
JP5858984B2 (ja) 2010-04-18 2016-02-10 イェダ リサーチ アンド デベロップメント カンパニー リミテッド ErbB/ErbBリガンドに関連する疾患を治療するための分子及びその分子を使用する方法
US10913767B2 (en) 2010-04-22 2021-02-09 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
WO2011133868A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Conformationally restricted dinucleotide monomers and oligonucleotides
EP2582842A2 (de) 2010-06-16 2013-04-24 Yissum Research Development Company of The Hebrew University of Jerusalem Verfahren zur diagnose und behandlung von krebs
WO2012035539A1 (en) 2010-09-15 2012-03-22 Ramot At Tel-Aviv University Ltd. Methods of expanding and redifferentiating islet beta cells
EP2627766B1 (de) 2010-10-17 2016-05-25 Yeda Research and Development Co. Ltd. Verfahren und zusammensetzungen zur behandlung von insulinassoziierten erkrankungen
EP2720720B1 (de) 2011-06-14 2018-02-28 Yeda Research and Development Co. Ltd. Kombinationstherapie zur verhinderung von dcis-bildung und deren fortschreiten zu brustkrebs
US9499793B2 (en) 2011-08-09 2016-11-22 Yeda Research And Development Co. Ltd. Downregulation of miR-7 for promotion of beta cell differentiation and insulin production
EP2771464B1 (de) 2011-10-27 2018-03-21 Yeda Research and Development Co. Ltd. Verfahren zur behandlung von karzinomen
US9617331B2 (en) 2011-11-27 2017-04-11 Yeda Research And Development Co. Ltd. Methods of regulating angiogenesis by administering agents which increase apoB-100 polypeptide
EP3401394A1 (de) 2012-02-22 2018-11-14 Exostem Biotec Ltd Erzeugung von neuralen stammzellen
WO2014174511A1 (en) 2013-04-21 2014-10-30 Yeda Research And Development Co. Ltd. Agents for downregulation of the activity and/or amount of bcl-xl and/or bcl-w
MX359191B (es) 2013-07-19 2018-09-18 Monsanto Technology Llc Composiciones y métodos para controlar leptinotarsa.
UA120426C2 (uk) 2013-11-04 2019-12-10 Монсанто Текнолоджі Елелсі Композиція та спосіб для боротьби з членистоногими паразитами та зараженням шкідниками
US20170042893A1 (en) 2014-02-03 2017-02-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Use of casein kinase i inhibitors for depleting stem cells
US11091770B2 (en) 2014-04-01 2021-08-17 Monsanto Technology Llc Compositions and methods for controlling insect pests
CN106604993A (zh) 2014-07-29 2017-04-26 孟山都技术公司 用于控制昆虫害虫的组合物和方法
WO2016016894A1 (en) 2014-07-30 2016-02-04 Yeda Research And Development Co. Ltd. Media for culturing pluripotent stem cells
WO2016030899A1 (en) 2014-08-28 2016-03-03 Yeda Research And Development Co. Ltd. Methods of treating amyotrophic lateral scleroses
EP3220945A2 (de) 2014-11-17 2017-09-27 Yeda Research and Development Co., Ltd. Verfahren zur behandlung von krankheiten im zusammenhang mit der mitochondrienfunktion
MX395326B (es) 2015-01-22 2025-03-25 Monsanto Technology Llc Composiciones y métodos para controlar leptinotarsa.
WO2016135716A1 (en) 2015-02-26 2016-09-01 Jacob Schneiderman Methods and compositions relating to leptin antagonists
EP3261612A1 (de) 2015-02-26 2018-01-03 Yeda Research and Development Co. Ltd Verfahren zur förderung des haarwuchses
WO2016179180A1 (en) 2015-05-04 2016-11-10 Monsanto Technology Llc Compositions and methods for controlling arthropod parasite and pest infestations
US20180161300A1 (en) 2015-05-11 2018-06-14 Yeda Research And Development Co., Ltd. Citrin inhibitors for the treatment of cancer
WO2016185457A1 (en) 2015-05-19 2016-11-24 Yeda Research And Development Co. Ltd. Methods of promoting lymphangiogenesis
MX2017014787A (es) 2015-05-21 2018-05-01 Yeda Res & Dev Poblaciones bacterianas para promover la salud.
WO2017015109A1 (en) 2015-07-17 2017-01-26 Alnylam Pharmaceuticals, Inc. Multi-targeted single entity conjugates
EP3331546B1 (de) 2015-08-03 2023-10-04 Biokine Therapeutics Ltd. Cxcr4-antagonist zur behandlung von krebs
IL289849B2 (en) 2015-11-10 2024-01-01 Nat Inst Biotechnology Negev Ltd Means and methods for reducing tumorigenicity of cancer stem cells
WO2017118985A1 (en) 2016-01-06 2017-07-13 Yeda Research And Development Co. Ltd. Compositions and methods for treating malignant, autoimmune and inflammatory diseases
CA3014792A1 (en) 2016-02-16 2017-08-24 Carnegie Mellon University Compositions for enhancing targeted gene editing and methods of use thereof
WO2017153982A1 (en) 2016-03-06 2017-09-14 Yeda Research And Development Co. Ltd. Method for modulating myelination
IL247368A0 (en) 2016-08-18 2016-11-30 Yeda Res & Dev Diagnostic and therapeutic uses of exosomes
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery
WO2019021289A1 (en) 2017-07-27 2019-01-31 The National Institute for Biotechnology in the Negev Ltd. SMAC / DIABLO INHIBITORS USEFUL IN THE TREATMENT OF CANCER
IL255664A0 (en) 2017-11-14 2017-12-31 Shachar Idit Hematopoietic stem cells with enhanced properties
WO2019116376A1 (en) 2017-12-17 2019-06-20 Yeda Research And Development Co. Ltd. Cop9 signalosome (csn) complex modulators and uses thereof
EP3749368A1 (de) 2018-02-08 2020-12-16 Yeda Research and Development Co. Ltd Verfahren zur identifizierung und verwendung von mitteln zur behandlung von mit darmbarrierefunktionsstörungen einhergehenden krankheiten
IL314908A (en) 2018-03-29 2024-10-01 Technion Res & Dev Foundation Vesicles comprising a pten inhibitor and uses of same
SG11202010910QA (en) 2018-05-07 2020-12-30 Alnylam Pharmaceuticals Inc Extrahepatic delivery
JP2022521010A (ja) 2019-02-21 2022-04-04 イッスム・リサーチ・デベロプメント・カムパニー・オブ・ザ・ヘブリュー・ユニバシティー・オブ・エルサレム リミテッド 薬物誘導性腎毒性を減少させるための方法
US20220211743A1 (en) 2019-05-17 2022-07-07 Alnylam Pharmaceuticals, Inc. Oral delivery of oligonucleotides
CA3147575A1 (en) 2019-07-29 2021-02-04 Yeda Research And Development Co. Ltd. Methods of treating and diagnosing lung cancer
US20230257745A1 (en) 2020-07-10 2023-08-17 Alnylam Pharmaceuticals, Inc. Circular siRNAs
WO2023283403A2 (en) 2021-07-09 2023-01-12 Alnylam Pharmaceuticals, Inc. Bis-rnai compounds for cns delivery
IL310716A (en) 2021-08-10 2024-04-01 Gamida Cell Ltd Engineered nk cells, methods of their production and uses thereof
EP4522742A2 (de) 2022-05-13 2025-03-19 Alnylam Pharmaceuticals, Inc. Einzelsträngige schleifenoligonukleotide
US12180140B2 (en) 2022-12-23 2024-12-31 Hongene Biotech Corporation Compounds and methods for liquid phase oligonucleotide synthesis
WO2024238385A2 (en) 2023-05-12 2024-11-21 Alnylam Pharmaceuticals, Inc. Single-stranded loop oligonucleotides

Also Published As

Publication number Publication date
PT92640A (pt) 1990-06-29
AU4838490A (en) 1990-07-10
EP0375408A1 (de) 1990-06-27
ES2069598T3 (es) 1995-05-16
AU640910B2 (en) 1993-09-09
WO1990006934A1 (en) 1990-06-28
DE68921315D1 (de) 1995-03-30
JPH04502407A (ja) 1992-05-07
DK120091D0 (da) 1991-06-20
PT92640B (pt) 1995-09-12
DE68921315T2 (de) 1995-08-03
EP0375408B1 (de) 1995-02-22
CA2006008C (en) 2000-02-15
EP0449972A4 (en) 1992-03-18
EP0449972A1 (de) 1991-10-09
CA2006008A1 (en) 1990-06-20
DK120091A (da) 1991-06-20

Similar Documents

Publication Publication Date Title
ATE118818T1 (de) Verfahren zur herstellung synthetischer oligonukleotide, die spezifisch an bestimmungsstellen auf duplex-dna-molekülen binden durch formen eines kolinearen triplex, die synthetischen oligonukleotide und verfahren zu ihrer herstellung.
Grundström et al. Oligonucleotide-directed mutagenesis by microscale ‘shot-gun’gene synthesis
ATE161587T1 (de) Technik des genetischen fingerabdrucks mit dns- vervielfältigung
DE69824716D1 (de) Methode zur sequenzierung von nukleinsäuren
ATE324464T1 (de) Eine in kaskaden verlaufende vervielfältigungsreaktion von nukleinsäuren
ATE239090T1 (de) Methode zum generieren von einzelsträngigen dna molekülen
ATE263237T1 (de) Effizientes verfahren zum auffinden von genfunktionen mittels bibliotheken zur funktionellen genomanwendung
ATE343638T1 (de) Oligonukleotidliganden mit hoher affinität für pdgf
DK51092D0 (da) Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
AU3728093A (en) Novel oligonucleotide arrays and their use for sorting, isolating, sequencing, and manipulating nucleic acids
DE69615411D1 (de) Verfahren zur Herstellung von Polynucleotiden mit erwünschten Eigenschaften mittels wiederholter Selektion und Rekombination
DE502588T1 (de) Verfahren zur Amplifizierung von Nukleinsäuresequenzen.
ATE106948T1 (de) Verfahren zur amplifizierung von nukleinsäuren.
DE69016826D1 (de) Verfahren zur Synthese von Ribonukleinsäure (RNS).
EP0285123A3 (de) Verfahren zur vollständigen Mutagenese von Nucleinsäuren
FI893526A0 (fi) Material och metod foer oekning av nukleinsyrahybridisering.
DE69233458D1 (de) Nukleinsäuretypisierung durch polymeraseverlängerung von oligonukleotiden unter verwendung von terminator-mischungen
JP2005521422A5 (de)
CN105925671A (zh) 一种从核酸样品富集目标序列核酸的方法
ATE212382T1 (de) Verfahren zur sequenzierung durch oligomerhybridisierung
EP2390258A8 (de) Polymerasen mit hoher Wiedergabetreue und Verwendungen davon
Collick et al. Minisatellite binding protein Msbp-1 is a sequence-specific single-stranded DNA-binding protein
DE69637041D1 (de) Dna-fragment, dieses enthaltender rekombinanter vektor und verfahren zur expression von fremdgenen unter dessen verwendung
EP0812911B1 (de) Methode zur Bildung makromolekularer Mikrogenpolymeren
DE59410068D1 (de) Verfahren zur spezifischen Klonierung von Nukleinsäuren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties